DALLAS, April 29, 2021 /PRNewswire/ -- Lantern
Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company
using its proprietary RADR® artificial intelligence
("A.I.") platform to improve drug discovery and development and
identify patients who will benefit from its portfolio of targeted
oncology therapeutics, announced today that RADR® has
exceeded 4.6 billion datapoints. This 16-fold increase in
datapoints over the past 12 months was also accompanied by other
significant improvements in the functionality, feature-set and
automation of the drug development platform as well as a
significant increase in the number of drugs, drug classes and
cancers covered by RADR®.
![RADR® RADR®](https://mma.prnewswire.com/media/1499896/RADR.jpg)
"We are extremely pleased to share the fact that we have
increased the number of biologically relevant and curated
datapoints that power our RADR® platform by 16-fold
since last May and nearly 4-fold since the beginning of the year.
The pace of data acquisition, curation, and tagging achieved during
this last campaign is well ahead of schedule and allows us to
increasingly focus on building a more complete and more powerful
library of algorithms and machine learning models aimed at rapidly
answering questions that are fundamental to oncology drug
development," stated Panna Sharma,
President and CEO of Lantern Pharma. "Our mission to build the
world's largest, most robust and most accurate A.I. driven platform
for precision oncology drug discovery and development is advancing
rapidly. The robustness of the datasets powering RADR®
is anticipated to continue to improve machine-learning results,
accelerate automation of other features and aid oncology drug
development for Lantern and our partners with the ultimate focus of
benefitting cancer patients."
Lantern is committed to growing and enhancing
RADR®, which it believes is among the largest
drug development platforms powered exclusively for oncology drug
development and rescue. The growing datapoints, and accompanying
functionality in the A.I. platform, allow scientists, biologists,
and engineers to collaborate on issues of drug activity, drug
response, patient stratification, and cancer biomarkers at a pace
which has been unachievable, until now. The developmental focus on
increasing the number of datapoints, and improving the performance,
power and biological relevance of the algorithms, is expected to
yield additional targeted indications for Lantern's current
pipeline of drug candidates. We expect that the platform will also
help in revealing additional compounds and therapies that can be
in-licensed and subsequently developed in a more efficient, and
potentially more targeted manner. Lantern has used
RADR® to uncover indications in multiple cancer
sub-types, including CNS (central nervous system) cancers,
drug-resistant lung cancers, lung cancer sub-types among
never-smokers and SMARCB1 mutated cancers (e.g. Atypical Teratoid
Rhabdoid Tumors).
Lantern has filed two additional patent applications directed to
the RADR® platform that further strengthen the Company's
leading position in using A.I. for cancer drug development and drug
rescue. The Company's patent applications are directed to using
machine learning to predict and discover gene signatures associated
with pharmaceutical agents, as well as using automated and machine
learning methods on genomic and biomarker data for rescuing,
repurposing and repositioning of pharmaceutical agents. Lantern
expects to continue developing novel A.I. and machine learning
functionality, methods and technologies that it will file patents
on both as core technologies and directed in the use of its
pipeline of drug candidates.
"As A.I. continues to transform drug development, platforms that
can provide a machine-learning, A.I. driven edge are becoming an
essential tool for companies to make informed, rapid decisions in
cancer indication selection, trial design, validation of mechanisms
and potential creation of combination therapy regimens," continued
Sharma. "Now, with every major cancer and drug class being covered
in our A.I. platform, Lantern can focus not only on accelerating
our portfolio, but also on developing collaborations that continue
to enhance and validate our platform while delivering insights for
our biopharma partners. These RADR® powered
insights are expected to accelerate development timelines, derisk
key decisions and uncover new opportunities that may have gone
undeveloped — ultimately leading to oncology therapies that can
increase the personalization of treatment."
"Biopharma companies are looking to launch programs in validated
indications more rapidly as they focus on maximizing the potential
of each drug candidate," said Mr. Sharma. "We believe that
RADR® can help design and launch these programs,
that continue to grow in complexity, at a fraction of the cost and
timeline of traditional oncology drug development. Creating novel
genomic and mechanistic insights while also providing specific
guidance on designing biomarker driven preclinical studies and
clinical trials is an essential component of personalizing cancer
treatment. RADR® is a powerful platform that can offer a
significant competitive advantage for oncology drug
development."
Contact
Marek Ciszewski, JD
Director, Investor Relations
628-777-3167
IR@lanternpharma.com
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage oncology-focused
biopharmaceutical company leveraging its proprietary
RADR® A.I. platform and machine learning to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
seven disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes. More information is available at:
www.lanternpharma.com and Twitter @lanternpharma.
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our
RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
the utilization of our RADR® platform to streamline the
drug development process; and our intention to leverage artificial
intelligence, machine learning and genomic data to streamline and
transform the pace, risk and cost of oncology drug discovery and
development and to identify patient populations that would likely
respond to a drug candidate. Any statements that are not statements
of historical fact (including, without limitation, statements that
use words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA
marketing approval or otherwise been incorporated into a commercial
product, (iii) the risk that none of our product candidates has
received FDA marketing approval, and we may not be able to
successfully initiate, conduct, or conclude clinical testing for or
obtain marketing approval for our product candidates, and (iv)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2020, filed with the Securities and
Exchange Commission on March 10,
2021. You may access our Annual Report on Form 10-K for the
year ended December 31, 2020 under
the investor SEC filings tab of our website
at www.lanternpharma.com or on the SEC's website
at www.sec.gov. Given these risks and uncertainties, we can
give no assurances that our forward-looking statements will prove
to be accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharmas-proprietary-ai-platform-for-precision-oncology-drug-development-radr-surpasses-4-6-billion-datapoints-accelerating-the-companys-progress-in-the-development-of-biopharma-collaborations-and-partnerships-and-a-301280045.html
SOURCE Lantern Pharma